Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.

G Bisogno; M Jenney; C Bergeron; Melcón S Gallego; A Ferrari; O Oberlin; M Carli; M Stevens; A Kelsey; Paoli A De; MN Gaze; H Martelli; C Devalck; European paediatric Soft tissue sarcoma Study Group

doi:10.1016/s1470-2045(18)30337-1

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.

G Bisogno, M Jenney, C Bergeron, Melcón S Gallego, A Ferrari, O Oberlin, M Carli, M Stevens, A Kelsey, Paoli A De, MN Gaze, H Martelli, C Devalck, European paediatric Soft tissue sarcoma Study Group

Departament de Pediatria, d’Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

175 Cites (Scopus)

Idioma original	No s'ha definit/desconegut
Revista	The Lancet. Oncology
DOIs	https://doi.org/10.1016/s1470-2045(18)30337-1
Estat de la publicació	Publicada - de juny 2018

Accés al document

10.1016/s1470-2045(18)30337-1

Altres arxius i enllaços

https://www.scopus.com/pages/publications/85048857368

Com citar-ho

Bisogno, G., Jenney, M., Bergeron, C., Gallego, M. S., Ferrari, A., Oberlin, O., Carli, M., Stevens, M., Kelsey, A., De, P. A., Gaze, MN., Martelli, H., Devalck, C., & Group, E. P. S. T. S. S. (2018). Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(18)30337-1

@article{b2ed0d7353f94373b26d4caa85751618,

title = "Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.",

author = "G Bisogno and M Jenney and C Bergeron and Gallego, \{Melc{\'o}n S\} and A Ferrari and O Oberlin and M Carli and M Stevens and A Kelsey and De, \{Paoli A\} and MN Gaze and H Martelli and C Devalck and Group, \{European paediatric Soft tissue sarcoma Study\}",

year = "2018",

month = jun,

doi = "10.1016/s1470-2045(18)30337-1",

language = "Indefinido/desconocido",

}

Bisogno, G, Jenney, M, Bergeron, C, Gallego, MS, Ferrari, A, Oberlin, O, Carli, M, Stevens, M, Kelsey, A, De, PA, Gaze, MN, Martelli, H, Devalck, C & Group, EPSTSS 2018, 'Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.', The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(18)30337-1

TY - JOUR

T1 - Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.

AU - Bisogno, G

AU - Jenney, M

AU - Bergeron, C

AU - Gallego, Melcón S

AU - Ferrari, A

AU - Oberlin, O

AU - Carli, M

AU - Stevens, M

AU - Kelsey, A

AU - De, Paoli A

AU - Gaze, MN

AU - Martelli, H

AU - Devalck, C

AU - Group, European paediatric Soft tissue sarcoma Study

PY - 2018/6

Y1 - 2018/6

UR - https://www.scopus.com/pages/publications/85048857368

U2 - 10.1016/s1470-2045(18)30337-1

DO - 10.1016/s1470-2045(18)30337-1

M3 - Artículo

C2 - 29941280

JO - The Lancet. Oncology

JF - The Lancet. Oncology

ER -